Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SUO-2002
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Suono Bio, Inc. Announces First Patient Dosed with its SuonoCalmTM Platform
Details : SuonoCalm (SUO-2002) is a therapeutic platform for the ultra-rapid administration of a wide range of medicines. The technology is being tested for the topical administration of mesalamine for the treatment of ulcerative colitis
Product Name : SUO-2002
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2023
Lead Product(s) : SUO-2002
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable